Objective: To discuss the impact of Danhong injection on the serum IL-6 and IL-17 level in patients with acute myocardial infarction after percutaneous coronary intervention (PCI). Methods: A total of 120 patients with ST-segment elevation myocardial infarction (STEMI) after PCI from June 2014 to January 2016 were selected and randomly divided into a control group and a research group, with 60 patients in each. All patients were treated with conventional treatments, while the research group were treated with Danhong injection on the basic of the control group. The improvements of clinical symptoms, electrocardiogram and adverse reactions were observed, the levels of IL-6 and IL-17 before and after treatment for 3, 7 d were detected, and the left ventricular ejection fraction (LVEF) and myocardial infarction area in the two groups were compared. The patients were followed-up for 6 months, in which the occurrence of the major adverse cardiovascular events (MACE) were observed. Results: The total effective rate was 90.00% in the research group, which was higher than that in the control group (76.67%), the difference was statistically significant (P<0.05). The levels of IL-6 were (56.38±10.75) ng/mL and (42.52±8.14) ng/mL in the research group after treatments for 3 and 7 d, which were lower than that in the control group [(62.73±12.08) ng/mL and (51.65±9.78) ng/mL], differences were statistically significant (P<0.05). The levels of IL-17 were (28.73±5.68) ng/mL and (22.54±4.55) ng/mL in the research group after treatment for 3 and 7 d, which were lower than that in control group [(34.39±6.21) ng/mL and (29.82±5.74) ng/mL], the difference was statistically significant (P<0.05). The LVEF was 54.72%±5.64% in the research group after treatment, which was higher than that in the control group (49.38%±4.57%), the difference was statistically significant (P<0.05). The myocardial infarction area was 10.64%±4.38% in the research group after treatments for 3 and 7 d, which was lower than that in the control group (16.74%±5.49%), the difference was statistically significant (P<0.05). The occurrence rate of MACE was 5.00%, while that in the control group was 16.67%, the difference was statistically significant (P<0.05). Conclusion: Patients with acute myocardial infarction after PCI in treatments of Danhong injection can reduce the levels of IL-6 and IL-17, improve cardiac function, reduce the myocardial infarction area, and lower the occurrence rate of MACE, which is worthy of clinical use.